Hosted on MSN3d
Health Canada approves GSK’s Ojjaara for myelofibrosis in anaemia patients
Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in ...
Yahoo Finance4d
Ojjaara (momelotinib) approved in Canada for the treatment of myelofibrosis in adults who have moderate to severe anemia
Ojjaara (momelotinib) is the only approved treatment for newly diagnosed and previously treated myelofibrosis patients i who ...
Pharmabiz3d
Health Canada approves GSK’s Ojjaara for the treatment of myelofibrosis in adults who have moderate to severe anaemia
Mississauga, Ontario Thursday, November 14, 2024, 09:00 Hrs [IST] ...
The American Journal of Managed Care7d
Lower Pharmacy Costs Give Ruxolitinib Edge for Patients With MF and Anemia
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
pharmaphorum1y
GSK gets wide FDA approval for myelofibrosis drug
Now given the trade name Ojjaara, GSK's once-daily oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor can be given as an alternative to other JAK inhibitors in the first-line setting ...
Hosted on MSN3mon
GSK slips as vaccine outlook is slashed
Specialty medicines performed particularly well, exceeding expectations by 6%, driven by strong sales of Dovato and a launch of Ojjaara, said analysts at Jefferies in a note. General medicines saw ...
Daily2d
GSK Ojjaara approved in Canada for treatment of myelofibrosis in adults who have moderate to severe anemia
Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...
Yahoo Finance3d
Health Canada approves GSK’s Ojjaara for myelofibrosis in anaemia patients
Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in adults with moderate-to-severe anaemia. The once-daily, oral treatment is ...
Medindia5d
Ojjaara (momelotinib) approved in Canada for the treatment of myelofibrosis in adults who have moderate to severe anemia
With most myelofibrosis patients becoming anemic over time, Ojjaara's approval represents a significant milestone to improve the outcomes of these patients while also highlighting GSK's commitment ...
Newswire4d
Ojjaara (momelotinib) approved in Canada for the treatment of myelofibrosis in adults who have moderate to severe anemia
About Ojjaara (momelotinib) xxiv Ojjaara has a differentiated mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor ...